Your browser doesn't support javascript.
loading
Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome.
Carboni, Johnathon; Thomas, Elizabeth; Gipson, Debbie S; Brady, Tammy M; Srivastava, Tarak; Selewski, David T; Greenbaum, Larry A; Wang, Chia-Shi; Dell, Katherine M; Kaskel, Frederick; Massengill, Susan; Reidy, Kimberly; Tran, Cheryl L; Trachtman, Howard; Lafayette, Richard; Almaani, Salem; Hingorani, Sangeeta; Gbadegesin, Rasheed; Gibson, Keisha L; Sethna, Christine B.
Afiliación
  • Carboni J; Division of Nephrology, Department of Pediatrics, Cohen Children's Medical Center of NY, New Hyde Park, NY, USA.
  • Thomas E; Division of Nephrology, Department of Pediatrics, Dell Children's Medical Center, University of Texas, Austin, TX, USA.
  • Gipson DS; Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
  • Brady TM; Division of Nephrology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Srivastava T; Section of Nephrology, Children's Mercy Hospital and University of Missouri, Kansas City, MO, USA.
  • Selewski DT; Division of Pediatric Nephrology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
  • Greenbaum LA; Division of Nephrology, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Wang CS; Division of Nephrology, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Dell KM; Center for Pediatric Nephrology and Hypertension, Cleveland Clinic Children's, Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA.
  • Kaskel F; Division of Nephrology, Department of Pediatrics, Children's Hospital at Montefiore, Bronx, NY, USA.
  • Massengill S; Division of Nephrology, Department of Pediatrics, Levine Children's Hospital, Charlotte, NC, USA.
  • Reidy K; Division of Nephrology, Department of Pediatrics, Children's Hospital at Montefiore, Bronx, NY, USA.
  • Tran CL; Division of Pediatric Nephrology, Department of Pediatrics and Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
  • Trachtman H; Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
  • Lafayette R; Division of Nephrology, Department of Pediatrics, Stanford University, Palo Alto, CA, USA.
  • Almaani S; Division of Nephrology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Hingorani S; Division of Nephrology, Department of Pediatrics, University of Washington, Seattle, WA, USA.
  • Gbadegesin R; Department of Pediatrics, Division of Nephrology, Duke University Medical Center, Durham, NC, USA.
  • Gibson KL; Division of Pediatric Nephrology, UNC Kidney Center, Chapel Hill, North Carolina, USA.
  • Sethna CB; Division of Nephrology, Department of Pediatrics, Cohen Children's Medical Center of NY, New Hyde Park, NY, USA. csethna@northwell.edu.
Pediatr Nephrol ; 39(7): 2161-2170, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38319465
ABSTRACT

BACKGROUND:

In the current study, longitudinal BP and lipid measurements were examined in a NEPTUNE cohort of children with newly diagnosed nephrotic syndrome (cNEPTUNE). We hypothesized that hypertensive BP and dyslipidemia would persist in children with nephrotic syndrome, regardless of steroid treatment response.

METHODS:

A multi-center longitudinal observational analysis of data obtained from children < 19 years of age with new onset nephrotic syndrome enrolled in the Nephrotic Syndrome Study Network (cNEPTUNE) was conducted. BP and lipid data were examined over time stratified by disease activity and steroid exposure. Generalized estimating equation regressions were used to find determinants of hypertensive BP and dyslipidemia.

RESULTS:

Among 122 children, the prevalence of hypertensive BP at any visit ranged from 17.4% to 57.4%, while dyslipidemia prevalence ranged from 40.0% to 96.2% over a median of 30 months of follow-up. Hypertensive BP was found in 46.2% (116/251) of study visits during active disease compared with 31.0% (84/271) of visits while in remission. Dyslipidemia was present in 88.2% (120/136) of study visits during active disease and in 66.0% (101/153) while in remission. Neither dyslipidemia nor hypertensive BP were significantly different with/without medication exposure (steroids and/or CNI). In regression analysis, male sex and urine proteincreatinine ratio (UPC) were significant determinants of hypertensive BP over time, while eGFR was found to be a determinant of dyslipidemia over time.

CONCLUSIONS:

Results demonstrate persistent hypertensive BPs and unfavorable lipid profiles in the cNEPTUNE cohort regardless of remission status or concurrent steroid or calcineurin inhibitor treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Presión Sanguínea / Dislipidemias / Hipertensión / Síndrome Nefrótico Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Presión Sanguínea / Dislipidemias / Hipertensión / Síndrome Nefrótico Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Nephrol Asunto de la revista: NEFROLOGIA / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos